Kiniksa Pharmaceuticals International (KNSA) Competitors $33.75 +0.17 (+0.51%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$33.44 -0.31 (-0.92%) As of 08/22/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. VRNA, BBIO, BPMC, ELAN, ROIV, GRFS, LEGN, RVMD, RYTM, and RNAShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Elanco Animal Health Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk. Which has more volatility & risk, KNSA or VRNA? Kiniksa Pharmaceuticals International has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Is KNSA or VRNA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Which has preferable valuation & earnings, KNSA or VRNA? Kiniksa Pharmaceuticals International has higher revenue and earnings than Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$529.33M4.73-$43.19M$0.04843.75Verona Pharma PLC American Depositary Share$221.67M38.97-$173.42M-$0.99-106.63 Do institutionals & insiders believe in KNSA or VRNA? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to KNSA or VRNA? In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 11 mentions for Kiniksa Pharmaceuticals International and 9 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.71 beat Kiniksa Pharmaceuticals International's score of 1.19 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend KNSA or VRNA? Kiniksa Pharmaceuticals International presently has a consensus price target of $41.17, indicating a potential upside of 21.98%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, indicating a potential upside of 3.26%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, research analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Verona Pharma PLC American Depositary Share 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 SummaryKiniksa Pharmaceuticals International beats Verona Pharma PLC American Depositary Share on 13 of the 16 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.49B$3.11B$5.76B$9.61BDividend YieldN/A2.23%4.41%4.10%P/E Ratio843.9621.1431.2226.05Price / Sales4.73346.56435.13103.72Price / CashN/A43.1937.7358.48Price / Book5.058.129.536.61Net Income-$43.19M-$54.72M$3.26B$265.65M7 Day Performance1.11%2.62%2.11%2.02%1 Month Performance24.45%2.68%2.80%-0.31%1 Year Performance23.27%10.93%30.59%19.04% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International2.6827 of 5 stars$33.75+0.5%$41.17+22.0%+28.8%$2.49B$529.33M843.96220Positive NewsInsider TradeVRNAVerona Pharma PLC American Depositary Share2.4062 of 5 stars$105.240.0%$109.00+3.6%+290.2%$8.96B$42.28M-106.3030Short Interest ↓BBIOBridgeBio Pharma4.6777 of 5 stars$48.24+3.6%$61.35+27.2%+97.2%$8.90B$221.90M-11.79400Insider TradeBPMCBlueprint Medicines0.4734 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ELANElanco Animal Health3.0825 of 5 stars$17.10+2.6%$17.33+1.3%+22.4%$8.28B$4.44B19.899,000Analyst DowngradeROIVRoivant Sciences3.4302 of 5 stars$11.17-2.8%$16.50+47.7%+2.1%$7.81B$29.05M-44.68860News CoverageInsider TradeGap DownGRFSGrifols3.5703 of 5 stars$10.60-0.6%$10.30-2.8%+14.8%$7.33B$7.81B9.0623,822Short Interest ↑LEGNLegend Biotech3.7919 of 5 stars$36.24-2.1%$73.00+101.4%-38.0%$6.80B$627.24M-61.422,609RVMDRevolution Medicines4.4082 of 5 stars$34.70-0.9%$68.82+98.3%-14.4%$6.54B$11.58M-7.71250News CoveragePositive NewsAnalyst RevisionRYTMRhythm Pharmaceuticals3.8231 of 5 stars$94.31+2.5%$101.57+7.7%+133.7%$6.11B$130.13M-31.33140News CoveragePositive NewsRNAAvidity Biosciences3.1733 of 5 stars$45.75-1.2%$67.00+46.4%+8.2%$5.96B$10.90M-15.25190Positive NewsInsider TradeOptions Volume Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access